English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Objective  The risk of cardiovascular disease ( CVD ) is higher in patients with psoriatic arthritis (PsA) compared to the general population. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Because tofacitinib increases circulating lipid levels in some patients, we evaluated  CVD  risk factors and major adverse cardiovascular events ( MACE ) in patients with active PsA receiving tofacitinib 5 or 10 mg twice daily plus conventional synthetic disease‐modifying antirheumatic drugs.    Methods  Data were pooled from 2 phase  III  studies (Efficacy and Safety of Tofacitinib in Psoriatic Arthritis [ OPAL  Broaden] and Tofacitinib in Patients with Psoriatic Arthritis With Inadequate Response to  TNF  Inhibitors [ OPAL  Beyond]) and 1 ongoing long‐term extension (Open‐Label Extension Study of Tofacitinib in Psoriatic Arthritis [ OPAL  Balance], data cutoff January 2017; database not locked). Outcomes included fasting lipid levels, blood pressure, hypertension‐related adverse events ( AE s; including hypertension, high blood pressure, and increased blood pressure), and  MACE .    Results  Overall, 783 tofacitinib‐treated patients were included. Percentage increases from baseline in low‐density lipoprotein cholesterol (LDL‐c) and high‐density lipoprotein cholesterol (HDL‐c) levels ranged from 9% to 14% for tofacitinib 5 mg and 10 mg at 3 and 6 months; no meaningful changes in  LDL ‐c: HDL ‐c or total cholesterol: HDL ‐c ratios were observed. Blood pressure remained stable for 24 months. Fifty‐eight patients (7.4%) had hypertension‐related  AE s; none were fatal (incidence rate [ IR ] per 100 patient‐years 4.81 [95% confidence interval (95%  CI ) 3.65–6.22]). Five patients (0.6%) had  MACE  (IR 0.24 [95%  CI  0.05–0.70]); 2 were fatal.    Conclusion  Serum lipid level increases at month 3 following tofacitinib treatment in PsA were consistent with observations in rheumatoid arthritis and psoriasis. The  IR  of hypertension‐related  AE s and  MACE  was low; long‐term follow‐up is ongoing.

arthritis care and research

Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase  III  and Long‐Term Extension Studies